Trial Profile
Erbitux MEtastatic Colorectal Cancer Strategy Study (ERMES): A Phase III Randomized Two Arm Study With FOLFIRI + Cetuximab Until Disease Progression Compared to FOLFIRI + Cetuximab for 8 Cycles Followed by Cetuximab Alone Until Disease Progression in First Line Treatment of Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ERMES
- 05 Jan 2024 Results for safety and efficacy , published in the Journal of Clinical Oncology
- 06 Jun 2023 Results assessing whether Early tumor shrinkage act as clinical dynamic predictor of efficacy of a less intensive maintenance strategy , presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology